Antiandrogen or estradiol treatment or both during hormone therapy in transitioning transgender women

Review found insufficient evidence to determine efficacy or safety of hormonal treatment approaches for transgender women in transition, indicating gap between current clinical practice and clinical research. Robust RCTs and controlled cohort studies are needed.

SPS commentary:

The single ongoing study identified in review is an RCT conducted in Thailand, comparing estradiol valerate plus cyproterone treatment with estradiol valerate plus spironolactone treatment. The primary outcome will be testosterone level at three month follow‐up.


Cochrane Database of Systematic Reviews